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BACKGROUND: Identification of novel biomarkers could provide prognostic information and improve risk stratification in patients 
with aortic stenosis (AS). YKL-40 (chitinase-3-like protein 1), a protein involved in atherogenesis, is upregulated in human 
calcific aortic valves. We hypothesized that circulating YKL-40 would be elevated and associated with the degree of AS 
severity and outcome in patients with symptomatic AS. 
METHODS: Plasma YKL-40 was analyzed in 2 AS populations, one severe AS (n=572) with outcome measures and one with 
mixed severity (n=67). YKL-40 expression in calcified valves and in an experimental pressure overload model was assessed. 
 
RESULTS: We found (1) patients with AS had upregulated circulating YKL-40 compared with healthy controls (median 109 versus 34 
ng/mL, P<0.001), but levels were not related to the degree of AS severity. (2) High YKL-40 levels (quartile 4) were associated with 
long-term (median follow-up 4.7 years) all-cause mortality (adjusted hazard ratio, 1.93 [95% CI, 1.37–2.73], P<0.001). (3) YKL-40 
protein expression in human calcifi valves co-localized with its putative receptor IL-13rα2 in close proximity to valve interstitial 
cells. (4) Myocardial YKL-40 increased in experimental pressure overload (6-fold in decompensated versus sham mice). 
CONCLUSIONS: YKL-40 levels were elevated in AS and associated with mortality but not with other metrics of disease severity 
including the degree of AS severity. Despite scientific rationale for its role in AS, the clinical utility of circulating YKL-40 as 
a biomarker is limited. 
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01794832. 
 




Aortic valve stenosis (AS) is the most common cause of 
left ventricular (LV) outflow obstruction and aortic valve 
replacement (AVR) surgery. It is the third most common 
cardiovascular disease after coronary artery dis- ease and 
hypertension.1,2  Due to changing demographics with an 
increasing elderly population, the burden of AS is 
predicted to increase.3,4  Progression of AS is an active 
process involving macrophage-driven inflammation, 
osteogenesis, and remodeling of the extracellular matrix 
comparable to, but also distinct from, atherogenesis.1,5 
YKL-40 (chitinase-3-like protein 1) is a plasma gly- 
coprotein and a member of the mammalian chitinase-like 
protein, secreted by several cell-types. In the presence 
of inflammation, activated macrophages and neutrophils 
are the most important cellular sources of YKL-40.6 The 
precise function of YKL-40 has not been established, 
but it plays a role in inflammation, fibrosis, and extracel- 
lular matrix remodeling.7 Bossé et al8 identified YKL-40 
as one of the most upregulated mRNAs in human cal- 
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WHAT IS NEW? 
• Biomarkers that can monitor progression, sever- 
ity, and prognosis of aortic stenosis are needed 
improve risk stratification and decision making 
regarding timing of aortic valve area and follow-up. 
• YKL-40 expression has been shown to be markedly 
upregulated in calcified aortic valves. 
• We found that circulating YKL-40 was not corre- 
lated with aortic stenosis severity but was associ- 
ated with poor prognosis. 
 
WHAT ARE THE CLINICAL IMPLICATIONS? 
• Circulating YKL-40 does not give useful informa- 
tion regarding severity of aortic stenosis and cannot 
contribute to decision making. 
• High circulating YKL-40 or an increase in levels over 
time may carry important prognostic information. 
 
 
Nonstandard Abbreviations and Acronyms 
 
AS aortic valve stenosis 
AVA aortic valve area 
AVR aortic valve replacement 
HR hazard ratio 
hsCRP high sensitivity C-reactive protein 
hsTnT high–sensitive troponin T 
LV left ventricular 
MACE major adverse cardiovascular events 
NT-proBNP N-terminal pro-B-type natriuretic peptide 
 
but data on circulating levels of YKL-40 in AS patients 
are lacking. 
Use of biomarkers could improve risk stratification in 
AS and aid clinical decision-making by providing prog- 
nostic information.  Recent  studies  using  NT-proBNP 
(N-terminal pro-B-type natriuretic peptide) and hsTnT 
(high–sensitive troponin T) demonstrated the value of 
biomarkers for evaluating patients with AS.9,10 Several 
studies revealed increased circulating YKL-40 in patients 
with atherosclerosis and heart failure and showed that 
high YKL-40 levels confer risk of long-term adverse out- 
come.6,11,12 Based on the enhanced YKL-40 mRNA levels 
in aortic calcified valves and similarities between AS and 
atherosclerosis, we hypothesized that circulating levels 
of YKL-40 may also be upregulated and associated with 
outcome (ie, all-cause mortality) in patients with severe 
symptomatic AS. To test these hypotheses, we evalu- 
ated if (1) circulating YKL-40 levels were increased in 
patients with AS versus healthy controls, correlated with 
hemodynamic measures, severity of AS, or mortality; (2) 
YKL-40 was expressed in calcified valves; and (3) myo- 
cardial YKL-40 was upregulated in an experimental AS 
mouse model using aortic banding. 
METHODS AND MATERIALS 
Patients 
The data from this study are available on request from the corre- 
sponding author (Dr Ueland). We determined circulating plasma 
YKL-40 in 2 populations of consecutively enrolled patients with 
AS, who had been evaluated for AVR, according to current guide- 
lines. Inclusion/exclusion criteria and details on AVR and outcome 
data in these populations are show in Figure I and Table I in the 
Data Supplement, while baseline demographics are presented in 
Table 1. Population 1 consisted of 2 cohorts with AS obtained 
from our tertiary center (Oslo University Hospital Rikshospitalet, 
Norway)  on  2  occasions.  Cohort  1:  One  hundred  thirty-six 
patients evaluated between May 2005 and January 2007. This 
was a cross-sectional design, and patients were followed for a 
mean 4.3 years, and data on all-cause mortality was obtained. 
Cohort 2: Four hundred thirty-six patients evaluated between May 
2010 and March 2013. A second blood  sample was obtained 
after  1-year  from  319  patients  in  this  cohort.  Patients  were 
followed for a mean 4.0 years, and data on all-cause mortality 
was obtained (see next paragraph). In addition, major adverse 
cardiovascular  events  (MACE)  were  a  prespecifi outcome in 
this cohort (see defi of  MACE  below).  A  second  popula- 
tion  (population  2;  URL:  https://www.clinicaltrials.gov;  Unique 
identifi NCT03422770)  consisted  of  62  patients  (Table  1) 
with confi  AS evaluated for AVR surgery or just followed at 
the out-patient clinic. These were consecutively enrolled between 
January and November 2018 at St Olav’s Hospital, Trondheim, 
Norway. This population was not followed for outcome. AS sever- 
ity in both populations was classifi according to guidelines.13,14 
For  comparison,  76  healthy  controls  without  AS  (no  AS) 
sampled between November 2009 and November 2010, with 
no history of chronic disease or use of any medications and 
normal basic clinical chemistry data (Table 1) were used. 
For evaluation of YKL-40 levels in AS and associations with 
AS severity (ie, aortic valve area [AVA] and aortic mean gra- 
dient), we combined both population 1 and population 2. For 
evaluation of outcome, population 1 was used for assessing 
all-cause mortality and cohort 2 of population 1 was used for 
accessing MACE, since these data were available only in the 
indicated populations and cohorts. 
Informed consent was obtained from each study subject. 
The study protocols were approved by the regional committee 
for ethics in medicine, including approval from local hospitals 
and complied with the Declaration of Helsinki. 
 
Mortality and MACE 
For population 1, we retrieved complete all–cause mortality 
data from the Norwegian National Cause  of  Death  Registry 
and the causes of  death was obtained from  the Norwegian 
Cause of Death Registry. For cohort 2  of  population  1,  we 
also reviewed the patients’ medical records from their operat- 
ing and local hospitals to acquire data regarding all adverse 
clinical events during the year following study inclusion. The 
composite end point of MACE comprised the time from base- 
line to diagnosis of transient ischemic attack, stroke, myocardial 
infarction, all–cause death or hospitalization for cardiovascular 
cause (endocarditis, myocarditis, heart failure, atrial fibrillation; 
Table I in the Data Supplement). To ensure completeness of 
data, we reviewed the official clinical coding system for diag- 




Table 1.   Control and Patient Characteristics 
 
 No AS AS 
Variables n=76 n=639 
Mean age, y 66±8 74±11* 
Male sex, n (%) 44 (57) 366 (57) 
Body mass index, kg/m2 25.0±3.3 26.0±4.3 
NYHA class III/IV … 264 (47) 
AVR … 448 (78) 
Severity AS, mild/moderate/ 
severe, n 
… 10/38/591 
Medical history, n (%) 
Hypertension 0 (0) 262 (41)* 
Atrial fibrillation, all types 0 (0) 137 (21)* 
Diabetes mellitus type I and II 0 (0) 63 (10)* 
Coronary artery disease 0 (0) 129 (20)* 
Medication, n (%) 
β-blocker 0 (0) 274 (43)* 
ACEi/ARB 0 (0) 241 (38)* 
Warfarin 0 (0) 111 (17)* 
Statin 0 (0) 314 (49)* 
Hemodynamics 
LVEF, % … 56±11 
Cardiac index, L/(min·m2) … 2.6±0.6 
IVS, cm … 1.0±0.2 
LVID, cm … 4.9±0.8 
LVPW, cm … 1.1±0.2 
E/A ratio … 1.0±0.5 
Aortic mean gradient, mm Hg … 53±19 
Aortic valve area, cm2 … 0.7±0.3 
Biochemistry 
Creatinine, µmol/L 75±14 85±31† 
eGFR, mL/min 87±14 74±3* 
NT-proBNP, ng/L median (IQR) 8 (4–13) 847 (313–2143)* 
Hs-TnT, ng/mL median (IQR) … 13 (10–24) 
Hs-CRP, mg/L 1.2 (0.8–2.2) 1.8 (0.8–4.9)‡ 
Categorical data is presented as n (%) while continuous data is given as 
mean±SD or median and 25th/75th percentile  depending  on  distribution. 
Full data sets were not available for all measures. ACEi indicates angiotensin- 
converting enzyme inhibitor; ARB, angiotensin receptor blocker; AS, aortic 
valve stenosis; AVR, aortic valve replacement; E/A ratio, ratio of the early (E) 
to late (A) ventricular filling velocities; eGFR, estimated glomerular filtration rate 
(Cockcroft–Gault formula); hs-CRP, high-sensitivity C-reactive protein; hs-TnT, 
high-sensitivity troponin T; IQR, interquartile range; IVS, intraventricular septum; 
LVEF, left ventricular ejection fraction; LVID, left ventricular internal diameter; 
LVPW, left ventricular posterior wall; NT-proBNP, N-terminal pro-B-type 





Classification of Diseases and Related Health Problems; ICD– 
10), and read the journal texts of each medical record. 
 
Echocardiography 
Dimensional   and   velocity   parameters   were   calculated   as 
described previously and are detailed in the Data Supplement.15 
Blood Sampling Protocol 
Peripheral venous blood was drawn into pyrogen-free EDTA 
tubes. The tubes were immediately immersed in melting ice 
and centrifuged within 30 minutes at 2000g for 20 minutes to 
obtain platelet-poor plasma. All samples were stored at −80°C 
and thawed <3×. 
 
Biochemistry 
NT-proBNP, hsCRP (high sensitivity C-reactive protein), hsTnT, 
and standard biochemistry was assayed as described,15 while 
plasma YKL-40 was  measured  by  enzyme  immune-assay 
(R&D Systems, Minneapolis, MN). See the Data Supplement 
for details. 
 
Aortic Valve Sampling 
For immunohistochemistry and immunofluorescence, aortic 
valve specimens were obtained from patients (n=4) undergo- 
ing elective AVR surgery with no history of other cardiac or con- 
comitant disease (n=2) or macroscopic signs of heart disease 
(n=2) obtained from autopsies. Aortic valve specimens were 
immediately immersed in formalin and then embedded in paraf- 
fin. For mRNA analysis, aortic valve specimens were obtained 
from 16 patients undergoing elective AVR surgery and immedi- 
ately flash frozen in liquid nitrogen and stored at −80°C. 
 
Immunohistochemistry  and 
Immunofluorescence 
For immunohistochemistry, 5μ sections of paraffin-embedded 
aortic valves were deparaffinised in xylene and hydrated in 




, followed by high- 
temperature antigen retrieval in citrate-buffer (pH 6), blocked 
with 0.5% BSA and then incubated with primary antibodies 
against human YKL-40 (polyclonal, 4815, QUIDEL, San Diego, 
CA; 1:100) or its putative receptor IL-13rα2 (Interleukin-13 
receptor subunit alpha-2; polyclonal, AF146, R&D systems, 
Oxon, United Kingdom; 1:25) for 1 hour at room temperature. 
After washing, the slides were incubated for 30 minutes with 
peroxidase-conjugated secondary antibody (Impress-Vector, 
Vector Laboratories, Burlingame, CA), rinsed, and developed 
with chromogen for immunoperoxidase staining (DAB Plus, 
Vector Laboratories) for 7 minutes. The sections were counter- 
stained with hematoxylin. Omission of the primary antibody was 
used as a negative control. 
For immunofluorescence, 5-micron sections of paraffin- 
embedded aortic valves were deparaffinized in xylene, rehy- 
drated in alcohol series and immersed in distilled water, followed 
by high-temperature antigen retrieval in citrate buffer (pH 6) 
and blocked with 0.5% BSA. The slides were stained with pri- 
mary antibodies against YKL-40 (polyclonal, 4815,  QUIDEL, 
San Diago, CA; 1:100), IL-13rα2 (polyclonal, AF146, R&D sys- 
tems, Oxon, United Kingdom; 1:25) and vimentin (monoclonal, 
M0725, Clone V9, Dako, Glostrup, DK; 1.100) for 1 hour  at 
room temperature and counterstained with Alexa Fluor F488 
goat anti-rabbit IgG (1:500), Alexa Fluor donkey anti-goat IgG 
(1:500) or Alexa Fluor 568 goat anti-mouse or Rat on Mouse 
AP Polymer kit in combination with Warp Red Chromogen kit 
(Biocare Medical, San Francisco, CA), respectively. The slides 




(Life Technologies, Carlsbad, CA). Images were taken by a 
Nikon Eclipse E400 microscope (Tokyo, Japan). 
 
Mouse Model of Experimental LV Pressure 
Overload 
The mouse models have been described in elsewhere16,17 (see 
the Data Supplement for details). 
 
mRNA Analysis 
Total RNA from mouse LV, human aortic valve specimens, and 
cardiac cells was extracted and analyzed as described.16 See 
the Data Supplement for details. 
 
Statistics 
Descriptive statistics are provided as frequencies and propor- 
tions for categorical variables, and as mean and SD or median 
and interquartile range as appropriate for continuous variables. 
Means and proportions were compared using χ2 tests for cat- 
egorical variables or t tests or the Kruskal Wallis test for con- 
tinuous variables. For survival analysis, Kaplan-Meier analysis 
with log-rank test was performed to compare the number of 
events in quartiles of YKL-40). The importance of YKL-40 as 
a risk factor for all-cause mortality was investigated by multi- 
variable Cox-regression with a predefined adjustment strategy 
as described previously.15 More details on the statistical meth- 
ods are given in the Data Supplement. 
YKL-40 between mild, moderate, and severe AS were 
detected. As shown in Figure 1D, YKL-40 correlated 
modestly with AVA (r=−0.20, P<0.001), but not with aor- 
tic mean gradient in AS (r=0.06, P=0.11). 
Table II in the Data Supplement shows correla- 
tions  between  YKL-40   and   demographic   features 
in patients with AS. YKL-40 correlated with mul- 
tiple variables including comorbidities, medications, 
and biochemistry, and multivariable linear regression 
revealed advancing age and New York Heart Associa- 
tion class, history of hypertension, warfarin use and 
high hsCRP and hsTnT levels as the strongest predic- 
tors  of  YKL-40  level. 
 
YKL-40 and Outcome 
As stated in methods, Table I and Figure I in the Data 
Supplement show details on outcome measures, includ- 
ing which populations they were available in, follow-up 
times and details on MACE. Data on all-cause mortality 
were available in population 1 (n=572), while MACE data 
were available in cohort 2 of population 1 (n=436). 
During a mean follow-up of 4.2 years (range, 0.1–6.8 
years) in population 1, 170 (30%) patients died; 78 (46%) 
in the nonsurgical group and 92 in the AVR (54%) group. 
Figure 2A shows an association between the concen- 
tration of YKL-40 and all-cause mortality, especially in 
  those with the highest YKL-40 levels (Q4). When evalu- 
RESULTS 
Characteristics of the Study Groups 
Table 1 shows demographics of patients with AS (popu- 
lation 1 and 2) and healthy controls (no AS). Compar- 
ing demographics between the patients and controls 
(Table 1) revealed a heathy control population that was 
younger, had better kidney function and as expected 
markedly lower NT-proBNP levels than patients with AS. 
 
YKL-40 Levels in Patients With AS 
Figure 1A shows the range of YKL-40 values in all 
patients with AS divided into quartiles.  Patients  with 
AS, on average, had higher YLK-40 levels than control 
patients, adjusted for age, gender, and body mass index 
(Figure 1B, P<0.001). Further adjustment for estimated 
glomerular filtration rate and NT-proBNP had no impact 
on this difference (P<0.001 using all covariates). Receiver 
operating characteristic analysis revealed good discrimi- 
nation of AS from controls (area under the curve=0.89, 
Figure 1B) and a cutoff of 51 ng/mL gave high sen- 
sitivity (0.97) and moderate specificity (0.79). YKL-40 
was inferior to NT-proBNP (area under the curve=0.93) 
but superior to hsCRP (area under the curve=0.60) for 
detection of AS. 
Figure 1C shows YKL-40 levels in all patients with 
AS according to severity. No significant differences in 
ating associations between YKL-40 alone and all-cause 
mortality in cox regression, we included AVR status, 
since this had a large effect on mortality. Thus adjusting 
for AVR gave a hazard ratio (HR) for all-cause mortality 
of 2.47 (95% CI, 1.81–3.37) for Q4. 
During the first year of follow-up, 22% of the patients 
in cohort 2 of population 1 experienced MACE, mostly 
due to hospitalization for cardiovascular causes (Table I in 
the Data Supplement). As depicted in Figure 2B, increas- 
ing  YKL-40  levels  were  associated  with  MACE.  This 
was mainly driven by patients experiencing MI, who had 
higher  YKL-40  levels  (mean  368  ng/mL)  than  patients 
experienced TIA/stroke (mean 134 ng/mL), were hospi- 
talized for cardiovascular causes (mean 207 ng/mL) or 
who died within the first year (mean 211 ng/mL). Com- 
paring Q4 of YKL-40 with the lower quartiles, adjusting 
for  AVR,  this  gave  a  HR  of  1.82  (1.19–2.78;  Table  2). 
Cox  models  for  All-Cause  mortality  and  MACE  using 
YKL-40 as a continuous variable with HR expressed per 
SD change in log YKL-40 gave similar results (Table 2). 
For multivariable analysis we used a predefined strat- 
egy established and reported for cohort 2.15  Adjustment 
variables were in addition to AVR status: age at inclusion, 
gender, estimated glomerular filtration rate), New York 
Heart Association class, left ventricular ejection fraction, 
NT-proBNP, hsTnT, hsCRP, AVA, symptoms (symptomatic 
or asymptomatic). Figure 3 shows all adjustment variables 





Figure 1. Plasma YKL-40 (chitinase-3- 
like protein 1) in patients with aortic 
stenosis (AS). 
A, Distribution of plasma levels of YKL-40 
in patients with AS (all patients, n=634). 
B, Plasma YKL-40 levels in patients with 
AS (population 1–2 combined) and in 76 
healthy controls (No AS). *P<0.001 in 
adjusted analysis including age, sex, body 
mass index (BMI), estimated glomerular 
fi rate (eGFR), and NT-proBNP 
(N-terminal pro-B-type natriuretic peptide). 
Receiver operating characteristic (ROC) 
curve with area under the curve and 
sensitivity/specifi determined at the 
optimal cutoff for discrimination of AS from 
controls (YKL-40=51 ng/mL). C, Plasma 
YKL-40 levels according to severity in 
all patients with AS, using age, BMI, sex, 
eGFR, and NT-proBNP as covariates. Data 
are given as Tukey plot with whiskers at 
2.5 and 97.5 percentiles in B and C. D, 
Correlation between YKL-40 and aortic 
valve area (AVA) and mean aortic gradient 
in all patients. hsCRP indicates high 
sensitivity C-reactive protein. 
 
 
to its large impact on mortality) as well as with full multi- 
variable adjustment. The association between Q4 YKL-40 
and all-cause mortality was attenuated in the multivariable 
model, but remained significant and indicated a 1.9 times 
(P<0.001) higher risk of death with high YKL-40 levels 
(Table 2). This gave a c-index in the full model (with YKL- 
40: 0.76 and without: 0.74, and a difference of 0.012, 
P=0.056). Low left ventricular ejection fraction was also 
significantly associated with death in the fully adjusted 
model. Adjustment for other clinical factors eliminated the 
association between YKL-40 and MACE (Table 2). 
 
YKL-40 During Follow-Up 
In population 1, cohort 2, a second blood sample was 
obtained after 1-year follow-up in 318 patients with AS 
(Figure I in the Data Supplement), with subsequent clini- 
cal follow-up with a median time of 4.9 years. Of these, 
66 patients died. The change in YKL-40 from baseline to 
follow-up was similar in AVR and non-AVR patients, and 
these were combined for further analysis. As shown in 
Figure 4A, a modest increase in YKL-40 was observed 
over time. Patients who had an increase in YKL-40 over 
time (ie, delta YKL40 >0 ng/mL, n=215, 68%) had 
poorer prognosis as evaluated by all-cause mortality 
(Figure 4B). 
 
Presence of YKL-40 in Calcified Aortic Valves 
To evaluate the presence of protein  levels  of  YKL-40 
and its putative receptor IL-13rα218 in calcifi aortic 
valves, we performed immunostaining of 4 aortic valves 
removed during AVR. Comparative immunohistochemi- 
cal analyses were performed on aortic valves from per- 
sons with no medical history or macroscopic signs of 
heart  disease  (n=2)  obtained  from  autopsies.  YKL-40 
 
 
Figure 2. Association between 
plasma YKL-40 (chitinase-3-like 
protein 1) and outcome in patients 
with severe aortic stenosis (AS). 
Kaplan-Meier curves showing the 
cumulative incidence of (A) all-cause 
mortality (n=170 deaths, median 
follow-up: 4.7 y) and (B) major adverse 
cardiovascular events (MACE, n=95) 
during the first year of follow-up according 
to quartiles of YKL-40. Quartile 1: <66 ng/ 
mL, quartile 2: 66–110 ng/mL, quartile 3: 




Table 2.   Univariate and Multivariable Cox Models for YKL-40 (Chitinase-3-Like Protein 1) Given as Hazard Ratios (95% 
CI) and P Values, Evaluated as Dichotomized at Quartile 4 and as a Continuous Variable With HR Expressed per SD 
Change in Log YKL-40, and Association With All-Cause Mortality In Population 1 and MACE in Population 1 Cohort 2 
 
 All-Cause Mortality MACE 
 n=572, Events n=170 (30%) n=436, Events n=95 (22%) 
Univariate* Multivariable Univariate* Multivariable 
YKL-40 Q4 2.47 (1.81–3.37); P <0.001 1.93 (1.37–2.73); P <0.001 1.82 (1.19–2.78); P= 0.006 1.34 (0.84–2.12); P=0.22 
YKL-40 log/SD 1.60 (1.37–1.88); P <0.001 1.35 (1.12–1.64); P= 0.002 1.42 (1.16–1.75); P= 0.001 1.12 (0.89–1.41); P=0.35 
HR indicates hazard ratio; and MACE, major adverse cardiovascular events. 
*Aortic valve replacement included in univariate analysis. Multivariable model: age, sex, aortic valve area, aortic valve replacement, estimated glomerular filtration rate, 
high-sensitivity C-reactive protein, high-sensitivity troponin T, left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide; New York Heart Association. 
 
and the putative receptor IL13rα2 were present and 
more abundant in the calcified aortic valves compared 
with normal ones, although large heterogeneity was 
seen. For YKL-40 and IL-13rα2, a  strong  cell  localiza- 
tion in fi cells was observed (Figure 5A and 
5B). This was supported by immunofl stain- 
ing showing co-staining with vimentin, a mesenchymal 
cell marker, of both YKL-40 (Figure 5C) and IL-13rα2 
(Figure 5D) supporting  the  expression  of  YKL-40  and 
its receptor in valve interstitial cells. 
In 16 patients (demographics in mean±SD or  %: 
age 70±12, 50% women, AVA 0.70±0.19, aortic mean 
gradient 57±28, 44%New York Heart Association 3), 
we determined mRNA levels of YKL-40 in aortic valves 
removed during AVR and protein level of YKL-40 in 
parallel plasma samples. However, no association was 
detected (r=0.28, P=0.30). 
 
 
Figure 3. Multivariable Cox regression of YKL-40 (chitinase- 
3-like protein 1) and all-cause mortality in patients with 
symptomatic aortic stenosis. 
Blue circles: hazard ratio (HR) and 95% CI adjusted for aortic valve 
replacement (AVR) status (n=572), red squares: HR and 95% CI  
in the fully adjusted multivariable model (n=496). AVA indicates 
aortic valve area; eGFR, estimated glomerular filtration rate; hsCRP, 
high-sensitivity C-reactive protein; hsTnT, high-sensitivity troponin T; 
LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro- 
B-type natriuretic peptide; and NYHA, New York Heart Association. 
*P<0.05, **P<0.01, ***P<0.001. 
YKL-40 During Experimental Pressure Overload 
To further examine the association between YKL-40 and 
AS, we examined the myocardial expression of YKL-40 
and IL-13rα2 in an experimental model of myocardial 
pressure overload (ie, aorta banding), relevant to AS. As 
shown in Figure IIA in the Data Supplement, we found 
significant myocardial upregulation of YKL-40 in hearts 
with compensated and decompensated (significantly 
increased wet lung weight) LV hypertrophy 3 weeks fol- 
lowing aorta banding as compared with sham-operated 
mice. In a separate experiment, we evaluated the cell 
specific expression of YKL-40 in sham-operated mice by 
measuring YKL-40 mRNA in 4 distinct cell populations 
within the heart (ie, cardiomyocytes, CD45+ leukocytes, 
CD31+ endothelial cells, and fibroblast-like cells; see 
Methods). YKL-40 mRNA levels were markedly higher in 
cardiac fibroblast-like cells, followed by leukocytes while 
expression was low in endothelial cells and cardiomyo- 




The  present  study  evaluated  YKL-40  in  clinical  and 
experimental AS. Our major findings were (1) we found 
enhanced plasma levels of YKL-40 in patients with AS 
compared  with  healthy  controls;  (2)  YKL-40  protein 
expression in human calcific valves co-localized with its 
putative  receptor  IL-13rα2  in  close  proximity  to  valve 
interstitial cells; (3) mice with chronic pressure overload 
displayed elevated myocardial YKL-40 mRNA levels. (4) 
While high YKL-40 was associated with poor prognosis 
in patients with AS , circulating levels were not associ- 
ated with the degree of AS severity. Thus, while patients 
with  AS  had  enhanced  plasma  levels  of  YKL-40,  we 
could not link YKL-40 levels to progression of disease, 
limiting its clinical utility as a biomarker in these patients. 
Previously, Bossé  et al8   identified  YKL-40 as  one of 
the most upregulated mRNAs in human calcified aortic 
valves, prompting the current study. Indeed, we found 
support  for  enhanced  YKL-40  expression  in  AS.  Clini- 
cal  AS  was  characterized  by  elevated  YKL-40  levels  in 
plasma compared with controls, and mice with chronic 






Figure 4. Plasma YKL-40 (chitinase-3-like protein 1) during 
follow-up in aortic stenosis (AS). 
A, YKL-40 levels at baseline and 1-year follow-up in 318 patients 
with AS from population 1 cohort 2. Data are shown as back- 
transformed logYKL-40 levels and reflect geometric mean and 95% 
CI. B, Kaplan-Meier analysis of all-cause mortality (n=66, 21%, 
median follow-up 4.9 y) according to if patients increased (↑ n=205) 
or decreased (↓ n=113) YKL-40 during follow-up. 
 
to AS, displayed elevated myocardial YKL-40 levels. Fur- 
thermore, in calcified valvular tissue from patients with 
AS, YKL-40 and its receptor co-localized in valve inter- 
stitial cells. However, a clinically useful biomarker in AS 
should reflect disease severity and potentially be used 
to determine the optimal timing of AVR. Further analysis 
revealed little support for a prominent role for YKL-40 
in AS progression or clinical utility as a biomarker. Thus, 
while present in calcified aortic valves, YKL-40 mRNA 
levels did not correlated with systemic levels. Importantly, 
circulating YKL-40 correlated poorly with the degree of 
valvular stenosis as reflected by hemodynamic indices 
(ie, AVA and gradient) and could not distinguish patients 
with mild, moderate, or severe AS. Taken together, while 
our data support the upregulation of YKL-40 in AS, the 
enhanced levels do not seem to be related to the patho- 
physiology or progression of the disease, and argue 
against further studies in these patients. 
YKL-40 seems to be a universal marker for infl - 
mation and extracellular matrix remodelling and is 
elevated in multiple disorders with an element of infl - 
mation and tissue remodelling,7,19 including coronary 
artery  disease.11,20 
The elevated YKL-40 levels in our patients with AS 
compared with healthy controls, but lack of association 
with severity of AS may suggest the higher levels reflect 
an element of atherosclerosis or other underlying vas- 
cular conditions. Indeed, a range of demographic vari- 
ables correlated with YKL-40 and could contribute to 
higher circulating levels including age, hsCRP, hyperten- 
sion, hsTnT, and New York Heart Association class. The 
elevated myocardial YKL-40 mRNA levels we observed 
in experimental pressure overload, with high expression 
in cells involved in inflammation, fibrosis, and extracel- 
lular matrix remodeling, suggest that these tissues could 
contribute to elevated systemic levels. In our study, high 
YKL-40 levels were independently associated with all- 
cause mortality. We and others have shown that YKL- 
40 levels are elevated and associated with prognosis in 
heart failure,11,12,21 a cause of death in unoperated AS.22 
Increased circulating YKL-40 in the general population 
is also associated with risk of death from multiple causes 
such as cardiovascular disease, cancer, and other chronic 
inflammatory diseases.19,23 Thus, YKL-40 seems to be a 
quite nonspecific marker of poor prognosis, further limit- 
ing its clinical usefulness. 
 
 
Figure 5. Localization of YKL-40 (chitinase-3-like protein 1) and its putative receptor IL-13rα2 (Interleukin-13 receptor subunit 
alpha-2) in calcified aortic valves. 
Immunostaining of (A) YKL-40 and (B) IL-13rα2 in valves from patients with symptomatic aortic stenosis (representative images obtained with 40× 
objective), the magnifi circular image shows cells with positive staining. Co-staining of YKL-40 and (C) vimentin (a marker of VICs) and (D) IL-13rα2 




Limitations of our study include a relatively low num- 
ber of patients in subgroup analyses. In particular, the 
number of patients with less severe AS in our study was 
limited, and a larger sample from patients at an earlier 
stage of AS with outcome data would provide more con- 
fidence. We also combined cohorts with varying data 
collection, different degrees of outcome ascertainment, 
and different duration of follow-up. Serial samples were 
available only in a small subset and particular caution 
needs to be taken with any conclusions drawn from 
those data. With experience, outcomes for TAVI have 
changed dramatically during the study period, for rea- 
sons we believe are unrelated to YKL-40 biology, so this 
cohort was not included in our analyses. Also, assess- 
ment of YKL-40 levels in blood from the coronary sinus 
and mRNA levels from myocardial tissue from patients 
with AS would give stronger information on the role and 
origin of YKL-40  in AS. 
In conclusion, YKL-40 levels were elevated in patients 
with AS. Circulating YKL-40 is increased in multiple dis- 
orders and seems universally associated with adverse 
outcome. The lack of association between circulating 
levels and the degree of AS severity in this study indi- 
cates that YKL-40 has low clinical utility as a biomarker 
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